Patents by Inventor Kwai-Ming J. Cheung
Kwai-Ming J. Cheung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897877Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: May 13, 2021Date of Patent: February 13, 2024Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20220402912Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: May 13, 2021Publication date: December 22, 2022Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 11046688Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: October 10, 2019Date of Patent: June 29, 2021Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20200165241Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: October 10, 2019Publication date: May 28, 2020Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 10479788Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: January 8, 2018Date of Patent: November 19, 2019Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20180141944Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: January 8, 2018Publication date: May 24, 2018Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 9895364Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: March 14, 2016Date of Patent: February 20, 2018Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Kwai-Ming J. Cheung, Butrus Atrash, Peter Sheldrake
-
Patent number: 9890157Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: April 6, 2016Date of Patent: February 13, 2018Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 9834552Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: April 6, 2016Date of Patent: December 5, 2017Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20160296514Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: March 14, 2016Publication date: October 13, 2016Inventors: Swen Hoelder, Julian Blagg, Kwai-Ming J. Cheung, Butrus Atrash, Peter Sheldrake
-
Patent number: 9409907Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: September 9, 2013Date of Patent: August 9, 2016Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20160222009Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: April 6, 2016Publication date: August 4, 2016Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20160220570Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: April 6, 2016Publication date: August 4, 2016Inventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 9334286Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: September 9, 2013Date of Patent: May 10, 2016Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Kwai-Ming J. Cheung, Butrus Atrash, Peter Sheldrake
-
Publication number: 20150239884Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: September 9, 2013Publication date: August 27, 2015Applicant: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Publication number: 20150218181Abstract: The present invention relates to compounds of formula II wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: ApplicationFiled: September 9, 2013Publication date: August 6, 2015Applicant: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Kwai-Ming J. Cheung, Butrus Atrash, Peter Sheldrake